SOUTH PLAINFIELD, NJ--(Marketwired - Apr 9, 2014) - GENEWIZ, Inc., leading global genomics service provider, today announced the launch of PGxOne™, a new, comprehensive pharmacogenomics test that provides clinically relevant data for personalized patient treatment.
Delivering immediately accessible and medically actionable data, PGxOne™ test results inform optimal drug selection and dosage based on an individual's genetic code. By screening an individual's DNA, personalized results decrease the risk of adverse drug effects while expediting effective patient treatment, thus increasing time and cost savings for patients, physicians, and payers.
"PGxOne™ enables comprehensive assaying of all well-established, medically relevant genetic variations, including substitutions, Indels, and copy number variance [CNV], in a single, cost-effective test," asserted Dr. Guanghui Hu, Vice President of Translational Genomics. "Having developed PGxOne™ with the latest next generation sequencing technologies, we are able to monitor and add new scientific discoveries to the test with great flexibility. This allows us to provide consistently accurate, actionable, and long-lasting results for patients."
Hu continued, "With the high quality data produced by PGxOne™, we have the opportunity to truly transform the impact of pharmacogenomic information on individual patient treatment, and to improve the effectiveness of healthcare."
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GLP regulatory-compliant services. GENEWIZ provides clinical genomic services from its established, CAP-accredited laboratory. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.